Practical implication
Pharmaceutical companies wishing to participate in the pilot must submit the same documentation to all involved national authorities, thus standardizing the submission process.
The European Medicines Agency (EMA) has published new guidance on a pilot program for a reliance model for post-authorisation changes (variations). This program permits pharmaceutical companies to leverage EMA assessment reports to support simultaneous submissions to regulatory authorities outside the EU, thus streamlining the approval process for safety-related updates.
What changed: The introduction of a reliance-based pathway allows non-EU regulators to utilize EMA's safety evaluations for faster global safety communication and label updates.
Why it matters: This change accelerates the implementation of safety-related updates across multiple jurisdictions, promoting consistent risk communication, and significantly reducing the time to update safety labels globally.
Practical implication: Pharmaceutical companies wishing to participate in the pilot must submit the same documentation to all involved national authorities, thus standardizing the submission process.
View original source
Published from the Firecrawl policy change extraction pipeline.
